Ventripoint Files AI Cardiac Imaging to NMPA, Exhibits at AEPC Congress
Lishman Global filed Ventripoint’s VMS+ 4.0 AI cardiac imaging system to China’s NMPA on April 28, 2026, seeking expedited approval for 330 million cardiovascular patients. On May 12–16, Ventripoint exhibited VMS+ 4.0 at the AEPC congress in Padua, demonstrating point-of-care MRI-equivalent volumetric assessments.
1. NMPA Submission to Chinese Regulator
On April 28, 2026, Ventripoint’s partner Lishman Global formally submitted the VMS+ 4.0 system to China’s National Medical Products Administration under the expedited “green channel” pathway, targeting access for an estimated 330 million cardiovascular disease patients and aiming to leverage China’s widespread echocardiography usage.
2. AEPC Exhibition in Padua
Between May 12 and 16, Ventripoint showcased VMS+ 4.0 at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, highlighting its ability to deliver rapid, MRI-equivalent volumetric cardiac measurements at the point of care for congenital heart disease follow-up.
3. Competitive Implications for GE Healthcare
Ventripoint’s regulatory push and high-profile European exhibition signal intensified competition in AI-driven cardiac imaging, potentially challenging GE Healthcare’s market share in volumetric assessment solutions and pressuring incumbents to accelerate validation and adoption efforts.